Business Description
Adaptimmune Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US00653A1079
Share Class Description:
STU:473A: ADRDescription
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.5 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 0.93 | |||||
| Debt-to-EBITDA | -1.3 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.23 | |||||
| Beneish M-Score | -1.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 120.5 | |||||
| 3-Year EBITDA Growth Rate | 10.3 | |||||
| 3-Year EPS without NRI Growth Rate | 11.6 | |||||
| 3-Year FCF Growth Rate | -22.2 | |||||
| 3-Year Book Growth Rate | -57.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.19 | |||||
| 9-Day RSI | 55.35 | |||||
| 14-Day RSI | 49.65 | |||||
| 6-1 Month Momentum % | -29.67 | |||||
| 12-1 Month Momentum % | 43.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.85 | |||||
| Quick Ratio | 3.82 | |||||
| Cash Ratio | 2.93 | |||||
| Days Sales Outstanding | 10.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.6 | |||||
| Shareholder Yield % | -25.7 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -25.76 | |||||
| Net Margin % | -25.43 | |||||
| FCF Margin % | -31.01 | |||||
| ROE % | -67.8 | |||||
| ROA % | -15.08 | |||||
| ROIC % | -39.29 | |||||
| ROC (Joel Greenblatt) % | -99.87 | |||||
| ROCE % | -30.65 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.06 | |||||
| PB Ratio | 2.3 | |||||
| Price-to-Tangible-Book | 2.43 | |||||
| EV-to-EBIT | -1.06 | |||||
| EV-to-EBITDA | -1.27 | |||||
| EV-to-Revenue | 0.42 | |||||
| EV-to-Forward-Revenue | 1.5 | |||||
| EV-to-FCF | -1.3 | |||||
| Price-to-Net-Current-Asset-Value | 22.67 | |||||
| Earnings Yield (Greenblatt) % | -94.23 | |||||
| FCF Yield % | -30.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adaptimmune Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 161.415 | ||
| EPS (TTM) (€) | -0.162 | ||
| Beta | 2.77 | ||
| Volatility % | 112.04 | ||
| 14-Day RSI | 49.65 | ||
| 14-Day ATR (€) | 0.033688 | ||
| 20-Day SMA (€) | 0.668 | ||
| 12-1 Month Momentum % | 43.5 | ||
| 52-Week Range (€) | 0.394 - 1.64 | ||
| Shares Outstanding (Mil) | 255.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adaptimmune Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adaptimmune Therapeutics PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Adaptimmune Therapeutics PLC Frequently Asked Questions
What is Adaptimmune Therapeutics PLC(STU:473A)'s stock price today?
The current price of STU:473A is €0.68. The 52 week high of STU:473A is €1.64 and 52 week low is €0.39.
When is next earnings date of Adaptimmune Therapeutics PLC(STU:473A)?
The next earnings date of Adaptimmune Therapeutics PLC(STU:473A) is 2025-03-06 Est..
Does Adaptimmune Therapeutics PLC(STU:473A) pay dividends? If so, how much?
Adaptimmune Therapeutics PLC(STU:473A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers